Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

[News]

Oncothyreon Inc. today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.

More... (http://www.news-medical.net/news/20091210/Merck-commences-Stimuvax-Phase-3-trial-in-Asian-patients-with-NSCLC.aspx)